DE60128916D1 - Neues, physiologisch aktives peptid und dessen verwendung - Google Patents
Neues, physiologisch aktives peptid und dessen verwendungInfo
- Publication number
- DE60128916D1 DE60128916D1 DE60128916T DE60128916T DE60128916D1 DE 60128916 D1 DE60128916 D1 DE 60128916D1 DE 60128916 T DE60128916 T DE 60128916T DE 60128916 T DE60128916 T DE 60128916T DE 60128916 D1 DE60128916 D1 DE 60128916D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- compound
- salt
- screening
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 238000012216 screening Methods 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217442 | 2000-07-18 | ||
| JP2000217442 | 2000-07-18 | ||
| JP2001026779 | 2001-02-02 | ||
| JP2001026779 | 2001-02-02 | ||
| PCT/JP2001/006162 WO2002006483A1 (fr) | 2000-07-18 | 2001-07-17 | Nouveau peptide actif sur le plan physiologique et utilisation associee |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60128916D1 true DE60128916D1 (de) | 2007-07-26 |
| DE60128916T2 DE60128916T2 (de) | 2007-09-20 |
Family
ID=26596235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60128916T Expired - Lifetime DE60128916T2 (de) | 2000-07-18 | 2001-07-17 | Neues, physiologisch aktives peptid und dessen verwendung |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7045299B2 (de) |
| EP (1) | EP1302542B1 (de) |
| AT (1) | ATE364698T1 (de) |
| AU (1) | AU2001272735A1 (de) |
| DE (1) | DE60128916T2 (de) |
| WO (1) | WO2002006483A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223727B2 (en) * | 1998-04-09 | 2007-05-29 | Serono Genetics Institute S.A. | GSSP4 polynucleotides and polypeptides and uses thereof |
| WO2001016309A1 (fr) * | 1999-08-27 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Proteine recepteur couplee a une proteine g et adn correspondant |
| US6485938B1 (en) * | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
| AU2002230778A1 (en) | 2000-11-03 | 2002-05-15 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
| EP1456656A4 (de) * | 2001-02-05 | 2005-09-21 | Bristol Myers Squibb Co | Neuer, mit dem orphan-gpcr gpr73 verwandter menschlicher g-protein-gekoppelter rezeptor hgprbmy14 |
| WO2003066860A1 (fr) * | 2002-02-04 | 2003-08-14 | Takeda Chemical Industries, Ltd. | Inhibiteurs d'angiogenese |
| EP1485107A1 (de) * | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipide als caspase-hemmer-prodrugs |
| AU2003284007A1 (en) | 2002-10-04 | 2004-05-04 | The Regents Of The University Of California | Screening and therapeutic methods relating to neurogenesis |
| US7205110B2 (en) * | 2002-10-07 | 2007-04-17 | Zymogenetics, Inc. | Uses of human Zven antagonists |
| EP1589033A4 (de) * | 2003-01-22 | 2006-04-12 | Takeda Pharmaceutical | Antikörper und dessen verwendung |
| WO2007033140A2 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
| JP2007121271A (ja) * | 2005-09-30 | 2007-05-17 | National Institute Of Advanced Industrial & Technology | ８−ヒドロキシ−２’−デオキシグアノシンの測定方法及び測定のための装置 |
| US20110020347A1 (en) | 2007-02-09 | 2011-01-27 | Takahiko Hara | Anti-brak (cxcl14) human monoclonal antibody and use thereof |
| JP5504513B2 (ja) * | 2008-02-19 | 2014-05-28 | 株式会社タニタ | カラム充填剤、これを用いたカラムおよび分離方法 |
| US20140134189A1 (en) | 2012-11-13 | 2014-05-15 | Regeneron Pharmaceuticals, Inc. | Anti-prokineticin receptor (prokr) antibodies and uses thereof |
| US9942187B2 (en) | 2014-03-10 | 2018-04-10 | Harry Leonard Perper | Alert for messages “stuck” in a message queue within a messaging application |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
| SG10202001102XA (en) | 2014-11-14 | 2020-03-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| CN107109407A (zh) | 2014-11-14 | 2017-08-29 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| EP3448987A4 (de) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| EP3458588B1 (de) | 2016-05-18 | 2025-10-29 | Voyager Therapeutics, Inc. | Modulatorische polynukleotide |
| EP3458589A4 (de) | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von morbus huntington |
| CA3035522A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| RU2662944C1 (ru) * | 2017-02-17 | 2018-07-31 | Общество с ограниченной ответственностью "Группа развития "АПЕКС" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования |
| AU2018261790B2 (en) | 2017-05-05 | 2024-10-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| EP3654860A1 (de) | 2017-07-17 | 2020-05-27 | Voyager Therapeutics, Inc. | Trajektoriearrayführungssystem |
| CN111448308A (zh) | 2017-08-03 | 2020-07-24 | 沃雅戈治疗公司 | 递送aav的组合物和方法 |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| EP3697908A1 (de) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Behandlung von amyotropher lateralsklerose (als) |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| WO2019173434A1 (en) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
| US20210207167A1 (en) | 2018-05-16 | 2021-07-08 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| CA3103963A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| CA3107462A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| CA3125770A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| EP3962536A1 (de) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systeme und verfahren zur herstellung von baculovirusinfizierten insektenzellen (biics) in bioreaktoren |
| US20220290182A1 (en) | 2019-08-09 | 2022-09-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4022070A1 (de) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Kontrollierte expression viraler proteine |
| EP4192514A1 (de) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20260085328A1 (en) | 2022-09-08 | 2026-03-26 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CN120543373B (zh) * | 2025-07-29 | 2025-10-03 | 中国海洋大学 | 基于递归双流Mamba的海温补全方法及系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000053753A2 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| WO1999063088A2 (en) * | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
| WO2000075327A1 (en) | 1999-06-02 | 2000-12-14 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| US5891720A (en) * | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
| AU8555198A (en) | 1997-08-01 | 1999-02-22 | Genset | 5' ests for secreted proteins expressed in prostate |
| EP1147136A4 (de) | 1998-12-10 | 2003-04-16 | Synaptic Pharma Corp | DNS, WELCHE FÜR EINEN REZEPTOR (fb41a) AUS SÄUGETIEREN KODIERT UND DEREN VERWENDUNGEN |
| AU3386800A (en) | 1999-03-01 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Secreted proteins and nucleic acids encoding them |
| EP1179066A2 (de) * | 1999-05-19 | 2002-02-13 | Incyte Genomics, Inc. | Extrazelluläre signalmoleküle |
| WO2001016309A1 (fr) * | 1999-08-27 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Proteine recepteur couplee a une proteine g et adn correspondant |
| WO2001036465A2 (en) | 1999-11-16 | 2001-05-25 | Zymogenetics, Inc. | Human zven proteins |
-
2001
- 2001-07-17 US US10/333,192 patent/US7045299B2/en not_active Expired - Fee Related
- 2001-07-17 EP EP01951893A patent/EP1302542B1/de not_active Expired - Lifetime
- 2001-07-17 DE DE60128916T patent/DE60128916T2/de not_active Expired - Lifetime
- 2001-07-17 WO PCT/JP2001/006162 patent/WO2002006483A1/ja not_active Ceased
- 2001-07-17 AT AT01951893T patent/ATE364698T1/de not_active IP Right Cessation
- 2001-07-17 AU AU2001272735A patent/AU2001272735A1/en not_active Abandoned
-
2005
- 2005-12-15 US US11/304,129 patent/US7419956B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60128916T2 (de) | 2007-09-20 |
| US7045299B2 (en) | 2006-05-16 |
| US20060088915A1 (en) | 2006-04-27 |
| US7419956B2 (en) | 2008-09-02 |
| AU2001272735A1 (en) | 2002-01-30 |
| EP1302542B1 (de) | 2007-06-13 |
| US20040077535A1 (en) | 2004-04-22 |
| ATE364698T1 (de) | 2007-07-15 |
| WO2002006483A1 (fr) | 2002-01-24 |
| EP1302542A1 (de) | 2003-04-16 |
| EP1302542A4 (de) | 2005-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60128916D1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| PL2157192T3 (pl) | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) | |
| DE60311272D1 (de) | Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten | |
| DE60311820D1 (de) | Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate | |
| ATE484494T1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| ATE316077T1 (de) | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| EP1978362A3 (de) | Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität | |
| ATE209684T1 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| DE60216457D1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| EA200501711A1 (ru) | Семейство секретируемых белков | |
| DE50212280D1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| DE60107888D1 (de) | Beta-Interferon zur Behandlung von Immunerkrankungen | |
| ATE491442T1 (de) | 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
| NO20034269L (no) | Anvendelse av forbindelser med den biologiske aktivitet til vaskoaktivt intestinalt peptid for behandlingen av kronisk obstruktiv pulmonalsykdom | |
| ATE353693T1 (de) | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen | |
| WO2002062944A2 (en) | Novel physiologically active peptide and use thereof | |
| DE10394363D2 (de) | Neue Chelidonin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen | |
| WO2002007676A3 (en) | Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) | |
| IL169256A (en) | Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE374260T1 (de) | Asthma-assoziiertes gen | |
| NO20052525D0 (no) | Spleisevariant av humant hypofyseveksthormon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |